Compare FLUX & RGNT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FLUX | RGNT |
|---|---|---|
| Founded | N/A | 2004 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.9M | 13.3M |
| IPO Year | 2019 | 2022 |
| Metric | FLUX | RGNT |
|---|---|---|
| Price | $0.55 | $1.81 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 374.7K | 22.5K |
| Earning Date | 05-07-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 5.00 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $9,317,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $23.01 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 126.25 | N/A |
| 52 Week Low | $0.47 | $1.23 |
| 52 Week High | $7.55 | $15.50 |
| Indicator | FLUX | RGNT |
|---|---|---|
| Relative Strength Index (RSI) | 42.40 | 42.60 |
| Support Level | $0.50 | $1.82 |
| Resistance Level | $0.63 | $2.27 |
| Average True Range (ATR) | 0.05 | 0.11 |
| MACD | -0.00 | -0.01 |
| Stochastic Oscillator | 15.95 | 31.71 |
Flux Power Holdings Inc. designs, develops, manufactures, and sells a portfolio of lithium-ion energy storage solutions for the electrification of a range of industrial and commercial sectors, which include material handling, airport ground support equipment (GSE), and stationary energy storage. It offers a high-power battery cell management system(BMS). The BMS serves as the brain of the energy storage solution, managing cell balancing, charging, discharging, monitoring, and communication between the pack and the forklift. The company's product portfolio includes Battery Technology and Energy Management solutions.
Regentis Biomaterials Ltd is a regenerative medicine company dedicated to developing tissue repair solutions that restore health and enhance the quality of life of patients. It is focused on orthopedic treatments using its Gelrin platform based on degradable hydrogel implants to regenerate damaged or diseased tissue (inflamed cartilage and bone tissue). Gelrin is a hydrogel matrix of polyethylene glycol diacrylate and denatured fibrinogen (a biologically inactivated protein that normally has a role in blood clotting). Its product is GelrinC, a cell-free, off-the-shelf hydrogel that is cured into an implant in the knee for the treatment of painful injuries to articular knee cartilage.